| First Author | Bernal-Mizrachi E | Year | 2001 |
| Journal | J Clin Invest | Volume | 108 |
| Issue | 11 | Pages | 1631-8 |
| PubMed ID | 11733558 | Mgi Jnum | J:73141 |
| Mgi Id | MGI:2154618 | Doi | 10.1172/JCI13785 |
| Citation | Bernal-Mizrachi E, et al. (2001) Islet beta cell expression of constitutively active Akt1/PKBalpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108(11):1631-8 |
| abstractText | The phosphoinositide 3-kinase-Akt/PKB pathway mediates the mitogenic effects various nutrients and growth factors in cultured cells. To study its effects in vivo in pancreatic islet beta cells, we created transgenic mice that expressed a constitutively active Akt1/PKBalpha linked to an Insulin gene promoter. Transgenic mice exhibited a grossly visible increase in islet mass, largely due to proliferation of insulin-containing beta cells. Morphometric analysis verified a six-fold increase in beta cell mass/pancreas, a two-fold increase in 5-bromo-2'-deoxyuridine incorporation, a four-fold increase in the number of beta cells per pancreas area, and a two-fold increase in cell size in transgenic compared with wild-type mice at 5 weeks. At least part of the increase in beta cell number may be accounted for by neogenesis, defined by criteria that include beta cells proliferating from ductular epithelium, and by a six-fold increase in the number of single and doublet beta cells scattered throughout the exocrine pancreas of the transgenic mice. Glucose tolerance was improved, and fasting as well as fed insulin was greater compared with wild-type mice. Glucose-stimulated insulin secretion was maintained in transgenic mice, which were resistant to streptozotocin-induced diabetes. We conclude that activation of the Akt1/PKBalpha pathway affects islet beta cell mass by alteration of size and number. |
